| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine
|
Infante, Jeffrey R.
|
|
2011
|
69 |
1 |
p. 137-144
|
artikel
|
| 2 |
A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects
|
Abbas, Richat
|
|
2011
|
69 |
1 |
p. 221-227
|
artikel
|
| 3 |
A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors
|
Infante, J. R.
|
|
2011
|
69 |
1 |
p. 165-172
|
artikel
|
| 4 |
A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer
|
Saridaki, Zacharenia
|
|
2011
|
69 |
1 |
p. 35-42
|
artikel
|
| 5 |
A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients
|
McCune, Jeannine S.
|
|
2011
|
69 |
1 |
p. 263-272
|
artikel
|
| 6 |
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen)
|
Reni, Michele
|
|
2011
|
69 |
1 |
p. 115-123
|
artikel
|
| 7 |
A systematic approach to the management of patients with brain metastases of known or unknown primary site
|
Kyritsis, Athanassios P.
|
|
2011
|
69 |
1 |
p. 1-13
|
artikel
|
| 8 |
Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial
|
Kim, Se Hyun
|
|
2011
|
69 |
1 |
p. 91-97
|
artikel
|
| 9 |
Different combination schedules of gemcitabine with endostar affect antitumor efficacy
|
Peng, Xing-Chen
|
|
2011
|
69 |
1 |
p. 239-246
|
artikel
|
| 10 |
5, 7-Dimethoxyflavone sensitizes TRAIL-induced apoptosis through DR5 upregulation in hepatocellular carcinoma cells
|
Yang, Jian-Feng
|
|
2011
|
69 |
1 |
p. 195-206
|
artikel
|
| 11 |
Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C14-erythromycin breath test and the antipyrine clearance test
|
Michael, M.
|
|
2011
|
69 |
1 |
p. 125-135
|
artikel
|
| 12 |
Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers
|
Kanai, Masashi
|
|
2011
|
69 |
1 |
p. 65-70
|
artikel
|
| 13 |
Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy
|
Holland, William S.
|
|
2011
|
69 |
1 |
p. 185-194
|
artikel
|
| 14 |
Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients
|
La-Beck, Ninh M.
|
|
2011
|
69 |
1 |
p. 43-50
|
artikel
|
| 15 |
5-Fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity
|
Jensen, Søren Astrup
|
|
2011
|
69 |
1 |
p. 57-64
|
artikel
|
| 16 |
Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination
|
Tavecchio, Michele
|
|
2011
|
69 |
1 |
p. 155-164
|
artikel
|
| 17 |
Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine
|
Joerger, M.
|
|
2011
|
69 |
1 |
p. 25-33
|
artikel
|
| 18 |
Hematologic adverse events associated with temozolomide
|
Villano, J. Lee
|
|
2011
|
69 |
1 |
p. 107-113
|
artikel
|
| 19 |
In vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin
|
Gan, Jinping
|
|
2011
|
69 |
1 |
p. 51-56
|
artikel
|
| 20 |
Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer
|
Qi, Wei-Xiang
|
|
2011
|
69 |
1 |
p. 99-106
|
artikel
|
| 21 |
Modification of uptake and subcellular distribution of doxorubicin by N-acylhydrazone residues as visualised by intrinsic fluorescence
|
Effenberger-Neidnicht, Katharina
|
|
2011
|
69 |
1 |
p. 85-90
|
artikel
|
| 22 |
Montelukast attenuates side effects of cisplatin including testicular, spermatological, and hormonal damage in male rats
|
Beytur, Ali
|
|
2011
|
69 |
1 |
p. 207-213
|
artikel
|
| 23 |
Pharmacokinetic characterization of a natural product–inspired novel MEK1 inhibitor E6201 in preclinical species
|
Kumar, Vipul
|
|
2011
|
69 |
1 |
p. 229-237
|
artikel
|
| 24 |
Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma
|
Reardon, David A.
|
|
2011
|
69 |
1 |
p. 281-287
|
artikel
|
| 25 |
Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer
|
Hong, Junshik
|
|
2011
|
69 |
1 |
p. 215-220
|
artikel
|
| 26 |
Population pharmacokinetics of PM00104 (Zalypsis®) in cancer patients
|
Pérez-Ruixo, Carlos
|
|
2011
|
69 |
1 |
p. 15-24
|
artikel
|
| 27 |
Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor
|
Wang, Dongchun
|
|
2011
|
69 |
1 |
p. 173-183
|
artikel
|
| 28 |
Regulation of chemosensitivity and migration by clusterin in non-small cell lung cancer cells
|
Cheng, Ching-Yuan
|
|
2011
|
69 |
1 |
p. 145-154
|
artikel
|
| 29 |
Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study
|
Gross, Mitchell E.
|
|
2011
|
69 |
1 |
p. 273-280
|
artikel
|
| 30 |
The marine sponge toxin agelasine B increases the intracellular Ca2+ concentration and induces apoptosis in human breast cancer cells (MCF-7)
|
Pimentel, Adriana A.
|
|
2011
|
69 |
1 |
p. 71-83
|
artikel
|
| 31 |
The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates
|
Marcus, Leigh
|
|
2011
|
69 |
1 |
p. 247-252
|
artikel
|
| 32 |
Triptolide augments the effects of 5-lipoxygenase RNA interference in suppressing pancreatic tumor growth in a xenograft mouse model
|
Ding, Xiaoling
|
|
2011
|
69 |
1 |
p. 253-261
|
artikel
|
Tijdschrift beschrijving